Investigation Of Selected Biochemical Markers In Knee Osteoarthritis: The Framingham Osteoarthritis Cohort
Luo, Yunyun; He, Y; Siebuhr, Anne Sofie; Hoielt, Sabine; Felson, David T; Karsdal, Morten; Bay-Jensen, A-C

Published in:
Annals of the Rheumatic Diseases

Publication date:
2017

Citation for published version (APA):
improvements over placebo were seen in 0.03 mg and 0.07 mg treatment arms, achieving statistical significance for PTGA and MDGA. Further studies to identify relevant sub-populations and evaluate the safety and efficacy of SM04690 are ongoing.


SAT0553 DETECTION OF SERUM LEVEL CHANGES OF MATRIX METALLOPROTEINASE-13 AND INTERLEUKIN-1BETA DURING REMISSION AND FLARE-UPS OF PRIMARY OSTEOARTHRITIS OF THE KNEES

Y. Hussein Gazar, H. Bassiouni. Alazhar University Hospital, Cairo, Egypt

Background: The diagnosis of osteoarthritis is currently based on radiographic criteria (e.g. joint space width) and clinical symptoms (e.g. pain and loss of function).

The evaluation of new disease-modifying osteoarthritis drugs (DMOADs) is performed on the same basis, since the regulatory bodies currently require evidence for an impact on radiographic joint space narrowing (JSN) and an impact on symptoms. However, the limitations of radiography have led to research into alternative parameters for monitoring osteoarthritis that could serve as biomarkers in drug development.

Objectives: Detection the serum level of MMP-13 and IL-1β in OA of the knee during remission and exacerbation.

Methods: This study was performed on 60 patients with knee osteoarthritis, 18 males (30%) and 42 females (70%), all diagnosed as osteoarthritis of one or both knees. Their ages ranged from (40–65) years. The duration of their disease ranged from one to 15 years. The control groups were 8 males (32%) and 17 females (68%), their ages ranged from (40–65) years.

The patients were allowed to continue on the medications that they have been taking. The biomarkers are evaluated in gold biomarkers in assessing OA progression and drug development in OA treatment.

Conclusions: There is a potential role for IL1 beta and MMP 13 biomarkers in assessing the development of osteoarthritis.

IL 1 β and MMP 13 were found to be correlated positively in patients with knee OA this correlation sounded right as the expression of MMP 13 depends on the level of IL1 β. Although all medications groups failed to lower the level of IL 1 β and MMP 13, yet there was a numerical difference in favor of Diacerein and NSAID.

Patients on both Diacerein and NSAID had the lowest rate of flare ups.

It is recommended that the early measurement of biomarkers may detect cases to progress and thus stronger treatment may be given for these groups.

Disclosure of Interest: None declared.

DOI: 10.1136/annrheumdis-2017-eular.1134

SAT0554 INVESTIGATION OF SELECTED BIOCHEMICAL MARKERS IN KNEE OSTEOARTHRITIS COHORT

Y. Luo1, Y. He1, A.S. Siebuhr1, S. Hoelt1, D. Felson2, M. Karsdal1, A.-C. Bay-Jensen1, 1 Biomarkers & Research, Nordic Bioscience, Herlev, Denmark; 2Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, United States

Background: Osteoarthritis (OA) is a major cause of functional impairment and disability among the elderly. There is an unmet need for the development of biomarkers for identifying patients with high risk for OA and for monitoring drug efficacy. Specific and sensitive biochemical markers revealing the turnover of bone, cartilage, and synovial tissue may be useful for investigation and monitoring of OA.

Objectives: To investigate a targeted set of five biochemical markers, which reflect joint tissue turnover, for their ability to evaluate the prevalence of radiographic and symptomatic knee osteoarthritis (OA) in a substudy from the cross-sectional Framingham OA cohort (FOA).

Methods: The subjects from the community-based FOA cohort were divided up based on a terminology proposed by the FNIH-OAI consortium. Two main groups were defined: subjects with radiographic knee OA (ROA, n=80) and a group with no radiographic OA (NROA, n=136). The presence of ROA as any Kellgren-Lawrence (KL) grade ≥2 or 3. The ROA group were further divided into two groups; those with persistent symptoms of a joint (ROA+S, n=30) and those without (ROA-S, n=50). +S was defined as having pain, aching or stiffness in either knee on most days.

Serum levels of C1M, CRP and huARGS (matrix metalloproteinases cleaved type I collagen and C-reactive protein neo-epitopes, aggrecanase cleaved 374ARGS neoepitope of aggrecan, Nordic Bioscience) were determined by ELISA. Serum levels of cartilage synthesis and degradation biomarkers, hPro-C2 and hSAGN1 (procollagen type II N-terminal propeptide, aggrecanase cleaved TEGE373 neoepitope of aggrecan, Nordic Bioscience) were measured by electrochemiluminescence immunoassay (ECLIA). Each measure was fisher transformed in order to be comparable across the biomarkers. The correlation between the biomarkers and OA diagnosis was assessed.

The subjects of sub-study were segregated into two groups based on the cut-off values of each biomarker. The cut-off values of these markers were set as mean of their reference levels. We used logistic regression to compare these two groups, and to examine the association between each marker and the presence of OA and/or pain. All confounding factors were adjusted.

Results: The two main groups were well-matched by age, sex, and BMI. Two biomarkers correlated negatively with BMI: C1M and CRP. Aggrecan degradation biomarker, hSAGN1 was negatively associated with age while the huARGS was not associated with it (Table 1). CRP was associated with a lower risk of ROA+S. Interestingly, hPro-C2 was associated with a higher risk of it (Table 2).

Table 1. Subject characteristics of sub-study

Table 2. Odds ratios of OA of the sub-study. Values in bold represent associations of p ≤0.05. OR data are for each definition of OA using logistic regression and adjusted for age, sex, and BMI (‘unpaired’; ‘unadjusted’). CIs are for comparison with subgroups with statistically significant values.

SAT0555 MRI-DETECTED KNEE OSTEOARTHY: NATURAL HISTORY AND STRUCTURAL RISK FACTORS AFFECTING CHANGE

Z. Zhu1, W. Han2, S. Zheng2, T. Winzenberg2, F. Ciucoli1, C. Ding2, G. Jones2

on behalf of Musculoskeletal Unit, Menzies Institute for Medical Research.

Background: Although magnetic resonance imaging (MRI) has been proved to be far more sensitive than conventional radiographs to detect OP, the natural history of MRI-detected OP in older adults has not yet been described, and it is unclear whether knee structural abnormalities, including cartilage defects, cartilage volume, bone marrow lesions (BMLs), meniscal extrusion, infrapatellar fat pad (IPFP), and effusion-synovitis, can predict osteophyte change.

Objectives: To describe the natural history of knee MRI-detected OP, and to determine if knee structural risk factors are associated with change of MRI-detected OP in a longitudinal study of older adults.

Disclosuar of Interest: None declared.

DOI: 10.1136/annrheumdis-2017-eular.1744

SAT0555 MRI-DETECTED KNEE OSTEOARTHY: NATURAL HISTORY AND STRUCTURAL RISK FACTORS AFFECTING CHANGE

Z. Zhu1, W. Han2, S. Zheng2, T. Winzenberg2, F. Ciucoli1, C. Ding2, G. Jones2

on behalf of Musculoskeletal Unit, Menzies Institute for Medical Research.

Disclosuar of Interest: None declared.

DOI: 10.1136/annrheumdis-2017-eular.1744